Zepzelca
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small-cell Lung Cancer
Conditions
Extensive-stage Small-cell Lung Cancer
Trial Timeline
Jun 28, 2021 → Jun 4, 2025
NCT ID
NCT04894591About Zepzelca
Zepzelca is a pre-clinical stage product being developed by Jazz Pharmaceuticals for Extensive-stage Small-cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04894591. Target conditions include Extensive-stage Small-cell Lung Cancer.
What happened to similar drugs?
0 of 7 similar drugs in Extensive-stage Small-cell Lung Cancer were approved
Approved (0) Terminated (1) Active (6)
🔄Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
🔄BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
3
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04894591 | Pre-clinical | Completed |
Competing Products
20 competing products in Extensive-stage Small-cell Lung Cancer